Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc at Piper Jaffray Healthcare Conference Transcript

Dec 03, 2019 / 02:00PM GMT
Edward Andrew Tenthoff
Piper Sandler & Co., Research Division - MD & Senior Research Analyst

Hi, my name is Ted Tenthoff. I'm a senior biotech analyst at Piper Jaffray. And before I begin, I'm required to point out certain disclosures regarding the relationship -- sorry, getting a little feedback -- with Piper -- there we go. That's better. And Moderna that approach both at the back of the room and also at the registration desk.

As you may have heard, Moderna is the leading developer of messenger RNA or mRNA therapy. The mRNA is the drug, and it actually induces endogenous expression of therapeutic proteins to treat different diseases. Moderna has a rich pipeline, so I want to jump right in to cover as much of the story as possible.

I'm pleased to introduce my good friend, CFO, Lorence Kim. Lorence, last year at the conference, you guys were on the road doing the IPO. So you weren't able to be here. So this is your first time. I'm happy to have you.

Lorence H. Kim
Moderna, Inc. - CFO & Treasurer

Thank you for having me. I'm so

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot